Arbutus Biopharma Corporation (ABUS)

[mick]

With a median price-to-sales (or "P/S") ratio of close to 11.8x in the Biotechs industry in the United States, you could be forgiven for feeling indifferent about Arbutus Biopharma Corporation's (NASDAQ:ABUS) P/S ratio of 12.4x. However, investors might be overlooking a clear opportunity or potential setback if there is no rational basis for the P/S.